John Parkinson

The Centers for Disease Control and Prevention (CDC) provided more information on a multistate outbreak and genomic testing.

Jacinda Abdul-Mutakabbir, PharmD, MPH, describes the university's atmosphere, students' involvement in community-based care, and the support they receive.

William Schaffner, MD, reviews clinical workup, treatment, and preventative measurements.

Nimish Patel, PharmD, discusses UC San Diego’s care offerings in HIV, the challenges of getting care to marginalized populations, and what the addition of lenacapavir means to individuals looking to access PrEP.

Jennifer Le, PharmD, MAS, FIDSA, FCCP, FCSHP, discusses her collaboration on this innovative work with this therapy in severely ill children.

Jennifer Le, PharmD, MAS, FIDSA, FCCP, FCSHP, talks about her work on the 2020 vancomycin guidelines for children as well as her efforts to implement Bayesian therapeutic drug monitoring for children in Vietnam.

In our continuing conversation with Victor Nizet, MD, he discusses how his laboratory is studying how to repurpose antibiotics that susceptibility testing had shown to not be efficacious against certain infections.

Victor Nizet, MD, talks about some of the work his laboratory is exploring, including how they want to take a similar approach to cancer treatment when developing antibiotics as well as the need to modernize susceptibility testing to reflect treatments' true utility.

Infectious disease pediatrician Sharon Nachman, MD, offers insights on what is already being done in clinical practice with regards to vaccines, the CDC committee's votes on the MMRV and hepatitis b vaccines, and understanding how they will affect these immunizations going forward.

Victor Nizet, MD, discusses how students can thrive at the university’s Skaggs School of Pharmacy and Pharmaceutical Sciences. He discusses the school's features including its rigorous coursework, focus on research, and community-based health care opportunities.

The non-vote leaves the current immunization recommendation in place, but led to further debate amongst the CDC's ACIP panelists on the hepatitis B vaccine as well as questioning the current process of the delivery of data and whether they would be utilizing working groups and grading studies.

The committee voted to change the MMRV vaccine recommendation, left panelists uncertain around a second MMRV immunization vote, and delayed the hepatitis B vaccine vote until Friday.

Ryan Shields, PharmD, MS, discusses the challenges of incorporating newer antibiotics for gram-negative infections, how he is using broad-spectrum antimicrobial agents for these infections, and the factors he looks for in considering new agents.

Monica V. Mahoney, PharmD, BCPS, BCIDP, FCCP, FIDSA, FIDP, FMSHP, provides insights on the outpatient side of therapy, including treating outpatients for gram-negative infections.

Rodney E. Rohde, PhD, SV/SM/MB(ASCP)CM, FACSc, offers some insights on the latest diagnostics, susceptibility testing for newer antimicrobials, and how infectious disease clinicians and laboratory professionals can collaborate on challenging cases.

The Los Angeles County Department of Public Health updated the public on the specific local case and reminds everyone of the importance of vaccination to protect the community.

Daniela Weiskopf, PhD, of the La Jolla Institute for Immunology, discusses her research in this area including the unique findings and pathways for therapeutics.

Merck reported the results for its phase 3 trial for its vaccine, Capvaxive, which was found to be noninferior to the pneumococcal 23-valent polysaccharide vaccine (PPSV23) for each of the 12 serotypes shared between the vaccines.

In the second installment of an interview with Jacinda Abdul-Mutakabbir, PharmD, MPH, she continues the discussion around limited to no health care engagement due to these factors, and the importance of translating data from the bench to bedside when looking at disease and infection prevention.

Jacinda Abdul-Mutakabbir, PharmD, MPH, provides insights on her recently published study on this topic and how the 2 are connected.

Michael Herce, MD, MPH, MSCR, discusses this concept and how it works to improve access to healthcare for populations who have been disproportionately burdened by various infectious diseases such as HIV, tuberculosis, and COVID-19.

In the second interview segment with leaders from UNC's Special Pathogen Center, they discuss what it is like to be in the field during an outbreak caring for patients with high-consequence infectious diseases, and offer insights on how well prepared the US is for these situations.

David Margolis, MD discusses his team’s work at UNC looking at combination treatment that includes the cancer drug, vorinostat, and immunotherapy as a potential HIV cure.

This becomes the first state in the United States to do so, and of course, this decision will affect the childhood vaccine schedule in Florida. Infectious Diseases Society of America (IDSA) President, Tina Tan, MD, weighs in on this decision and what this could mean for an increase of vaccine-preventable diseases and who would be vulnerable to them.

Jonathan Parr, MD, MPH, discusses his research about this deadly and burdensome disease and how he and his team identify these parasitic strains with a combination of epidemiologic field work and the latest laboratory technology.

Robert Hopkins, Jr, MD, medical director of the National Foundation for Infectious Diseases (NFID), discusses what patients are asking about with regards to the vaccines and what the general public should continue to know about their medical value.

UNC’s Sarah Rutstein, MD, PhD, discusses her research uncovering the inability of some people to receive HIV prevention medication in both the US and Africa and strategies to address it.

Joseph Eron, MD, provides insights on the unit's international reach as well as some of the important trials it has been involved in, notably the PURPOSE studies involving the landmark trials about lenacapavir for HIV prevention.

UNC’s Benjamin Smith, MD, provides some insights into the logistics and steps behind these complicated and serious missions.

Leaders from the UNC Special Pathogens Response Center discuss how they plan and carry out biopreparedness trainings to address transport and care of patients with high-consequence infectious diseases, such as Ebola or Lassa fever.